Press Releases

Eisai Co., Ltd. announced today that it has entered into a joint research agreement with four research organizations (KAN Research Institute, National Center for Global Health and Medicine, Nagasaki University, and Yokohama City University) in Japan concerning the "Development of Therapeutics to Prevent the Aggravation of the Novel Coronavirus Infectious Disease (COVID-19)" (Grant Number: 20fk0108255), which is a research project with Eisai as the representative research organizatio

Biocartis Group NV, an innovative molecular diagnostics company, announces the market release of SeptiCyte® RAPID on Idylla™ as a CE-marked IVD test. SeptiCyte® RAPID is a host-response test1 that distinguishes sepsis from non-infectious systemic inflammation in patients suspected of sepsis and provides actionable results in about one hour. The test was developed by Biocartis’ partner Immunexpress Pty Ltd (‘Immunexpress’), a Seattle-based (US) molecular diagnos

Applied BioMath, the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, announced a two-year strategic partnership with Xilio Therapeutics.  Applied BioMath will provide a variety of services related to mathematical modeling, simulation, analysis, and visualization, which include systems pharmacology, quantitative systems pharmacology, experiment prioritization and design, and traditional and mecha

BridgeBio Pharma, Inc. , a company focused on genetic diseases, and Eidos Therapeutics, Inc., a company focused on transthyretin (TTR) amyloidosis (ATTR), announced they have entered into a definitive agreement under which BridgeBio has agreed to acquire all of the outstanding common stock of Eidos it does not already own, representing approximately 36.3% of Eidos’ outstanding shares. Eidos stockholders will have the right to receive in the transaction, at their election, either 1.85 sh

Informa Markets announces its complete listing of pharma event dates for 2021 at the opening of the first CPhI Festival of Pharma (05 - 16 October 2020) – the largest ever virtual pharma event. The pharma schedule includes one further event in 2020: CPhI China, 16-18 December (hybrid event, combining “live” in-person with “virtual”). In 2021, all eight international CPhI editions [Worldwide, India, China, North America, Middle East & Africa, South E

Since the in-person PACK EXPO International and Healthcare Packaging EXPO have been cancelled, the process and packaging technology specialist Syntegonis presenting its latest solutions at the virtually-hosted PACK EXPO Connects from November 9 to 13, 2020. In a series of video and Q&A sessions, Syntegon is showcasingits intelligent and sustainable technologies for the pharmaceutical and food industries – including customer servicesand digital solutions. Visitors can now register fo

The U.S. Food and Drug Administration approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery. This is the first drug regimen approved for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma. "Today's approval of nivolumab plus ipilimumab provides a new treatment that has demonstrated an improvement in overall survival f

Qualigen Therapeutics, Inc.  announces it has entered into an amended Sponsored Research Agreement with the University of Louisville (UofL) to advance development of Qualigen's anticancer drug candidate AS1411-GNP, also known as ALAN (Aptamer-Linked Anti-Nucleolin).  The work being performed under the original Sponsored Research Agreement comprises animal studies to assess antitumor efficacy and safety of different ALAN compositions designed to treat pediatric and adul

Navigo Proteins GmbH, a premier protein engineering company specializing in novel affinity ligand development, and Repligen Corporation, a life sciences company focused on bioprocessing technology leadership today announced their successful development of an affinity ligand targeting the SARS-CoV-2 spike protein, to be utilized in the purification of COVID-19 vaccines. The program has entered stage two, which is focused on both scaling up manufacturing of this ligand, and on the development a

TaiGen Biotechnology Company, Limited announced that they have signed an exclusive licensing agreement with Luminarie Canada Inc. ("Luminarie"), a leading Canadian pharmaceutical company, to develop and commercialize Taigexyn® (nemonoxacin) in Canada, Australia and New Zealand. Taigexyn® is a novel safe and effective antibiotic for the treatment of bacterial infections including those caused by drug-resistant bacteria. Under the terms of the agreement, Luminarie will be resp